ALLMedicine™ Meningioma Center

Jan 27th, 2023 - Stereotactic radiosurgery (SRS) is an effective adjuvant therapy for residual tumor after subtotal resection of parasellar meningiomas. Fat graft placement between the optic nerve/chiasm and residual tumor (optic neuropexy [OPN]) allows for safe S...

Jan 27th, 2023 - In Reply: Transcriptomic Profiling Revealed Lnc-GOLGA6A-1 as a Novel Prognostic Biomarker of Meningioma Recurrence.|2023|Balik V,Slavik H,Srovnal J,|

Jan 25th, 2023 - Benign intracranial meningioma is one of the most common primary brain neoplasms. Proton therapy has been increasingly utilized for nonoperative management of this neoplasm, yet few long-term outcomes studies exist. The medical records of a total ...

Jan 24th, 2023 - Detecting brain tumors in their early stages is crucial. Brain tumors are classified by biopsy, which can only be performed through definitive brain surgery. Computational intelligence-oriented techniques can help physicians identify and classify ...

Jan 23rd, 2023 - Subfrontal meningiomas grow insidiously in areas with high cerebral compliance and a relative scarcity of eloquent function. Symptoms develop progressively, are nonspecific, and include anosmia, changes in personality and cognition, depressive sym...

May 29th, 2020 - Stereotactic radiosurgery (SRS) for benign intracranial meningiomas is an established treatment. To summarize the literature and provide evidence-based practice guidelines on behalf of the International Stereotactic Radiosurgery Society (ISRS). Ar...

Jan 18th, 2023 - Somatostatin receptors regulate cell growth through downstream modulation of both proliferation and apoptosis signaling pathways, and thus represent a potential therapeutic target. Lutathera (Lutetium [Lu]177 Dotatate) is a radionuclide therapy wh...

Jan 12th, 2023 - PRIMARY OBJECTIVES: I. To estimate the efficacy of lutetium Lu 177 dotatate (LUTATHERA) treatment in patients with recurrent grade 1 meningioma as measured by 6-month progression-free survival (PFS) rate. II. To estimate the efficacy of LUTATHERA ...

Jan 12th, 2023 - PRIMARY OBJECTIVES: I. To determine, in terms of progression-free survival (PFS), the extent of clinical benefit of the addition of adjuvant radiotherapy (RT) to gross total resection (GTR) for patients with newly diagnosed World Health Organizati...

Jan 11th, 2023 - This research is a Phase II clinical trial, which means it will test the safety and effectiveness of nivolumab alone (Cohort 1) or in combination with ipilimumab (Cohort 2). Both nivolumab and ipilimumab are antibodies (types of human protein) tha...

Jan 4th, 2023 - Meningioma are slow growing and frequently occurring intracranial tumors, responsible for 33% of all asymptomatic intracranial tumors and 13-26% of all symptomatic primary brain tumors. The 10-year survival rate is 72%. A variety of treatment opti...

Oct 17th, 2022 - Children who received cranial radiotherapy to treat their cancer faced an increased risk of developing meningioma — the most common type of benign brain tumor — decades after being exposed, according to a recent analysis. More specifically, among ...

Oct 13th, 2022 - The study covered in this summary was published on researchsquare.com as a preprint and has not yet been peer reviewed. Key Takeaway Although rare, radiation-induced meningiomas have higher-grade histology, require more aggressive treatment, and h...

Sep 8th, 2022 - "Polypills" Lower Cardiac Events "Polypills" can prevent certain cardiac events and deaths in at-risk patients, a new study found. Polypills — which combine aspirin, an angiotensin-converting enzyme inhibitor, and a statin — can lower the risk in ...

Sep 7th, 2022 - Adhering to American Cancer Society (ACS) guidelines on nutrition and physical activity can help lower the risk of obesity-related cancers in Black and Latina women, new research shows. Women who followed the lifestyle guidelines had a 28% to 42% ...

Jun 29th, 2022 - B7-H3, a member of the same protein family as PD-L1, has garnered attention as one of a slew of alternative targets riding the wave of success of immune checkpoint inhibitors (ICIs) in cancer immunotherapy.1 Also known by the name of the CD276 gen...